Q1 25 EPS
$-0.98
BEAT +23.04%
Est. $-1.27
Q1 25 Revenue
$20.0M
BEAT +23.87%
Est. $16.2M
vs S&P Since Q1 25
+35.5%
BEATING MARKET
SNDX +69.6% vs S&P +34.1%
Market Reaction
Did SNDX Beat Earnings? Q1 2025 Results
Syndax Pharmaceuticals delivered a strong double beat in Q1 2025, with the commercial momentum behind its newly launched oncology drugs driving results well ahead of Wall Street expectations. The company posted a net loss of $0.98 per share, beating … Read more Syndax Pharmaceuticals delivered a strong double beat in Q1 2025, with the commercial momentum behind its newly launched oncology drugs driving results well ahead of Wall Street expectations. The company posted a net loss of $0.98 per share, beating the consensus estimate of $1.27 by 23.04%, while revenue of $20.04 million cleared estimates of $16.18 million by 23.87%, fueled almost entirely by Revuforj net product sales marking its first full quarter on the U.S. Market. The standout performance drew analyst attention, with at least one major Wall Street firm raising its price target on the stock, citing Revuforj sales that roughly doubled initial projections. The net loss nonetheless widened to $84.85 million as SG&A expenses nearly doubled to $41.03 million year-over-year to support the commercial build-out, and R&D costs rose to $61.64 million including a $10.00 million milestone payment. Looking ahead, Syndax guided for full-year 2025 total operating expenses of $415 million to $435 million, while management expressed confidence that its $602.13 million cash position is sufficient to carry the company to profitability.
Key Takeaways
- • First full quarter of Revuforj U.S. launch generating $20.0 million in net revenue
- • First partial quarter of Niktimvo U.S. launch generating $13.6 million in net revenue (reported by Incyte)
- • Excellent commercial execution and clinical profile of first- and best-in-class medicines
SNDX YoY Financials
Q1 2025 vs Q1 2024, source: SEC Filings
SNDX Revenue by Segment
With YoY comparisons, source: SEC Filings
“I'm very pleased to report an outstanding quarter in which Revuforj and Niktimvo generated a combined $34 million in net sales. We believe this success is a reflection of excellent commercial execution and the clinical profile of these first- and best-in-class medicines.”
— Michael A. Metzger, Q1 2025 Earnings Press Release
SNDX Earnings Trends
SNDX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
SNDX EPS Trend
Earnings per share: estimate vs actual
SNDX Revenue Trend
Quarterly revenue: estimate vs actual
SNDX Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $-0.59 | $-0.48 | +18.75% | $64.9M | -7.11% |
| Q4 25 MISS FY | $-0.58 | $-0.78 | -34.88% | $68.7M | +6.15% |
| FY Full Year | — | $-3.29 | — | $172.4M | — |
| Q3 25 BEAT | $-0.71 | $-0.70 | +1.55% | $45.9M | -4.38% |
| Q2 25 BEAT | $-1.01 | $-0.83 | +17.50% | $38.0M | +42.48% |
| Q1 25 BEAT | $-1.27 | $-0.98 | +23.04% | $20.0M | +23.87% |